Novo Nordisk taps OpenAI

Novo Nordisk said Tuesday it is bringing OpenAI into drug research, factories and sales operations, with pilot projects starting immediately. (biospace.com) The Danish drugmaker said the partnership will use OpenAI tools to analyze large datasets, spot possible drug candidates and cut the time from research to patient use. Novo Nordisk said broader integration is planned by the end of 2026. (biospace.com) Novo Nordisk said the rollout will start in research and development, manufacturing and commercial operations. The company also said OpenAI will help train Novo Nordisk’s global workforce in artificial intelligence use. (biospace.com) Drugmakers have been trying to use artificial intelligence as a pattern-finding tool: software sifts through huge volumes of biology, chemistry and clinical data that humans cannot review quickly. Novo Nordisk said that is the point here too, and CNBC noted companies are also using artificial intelligence in clinical-trial planning and other slow parts of development. (biospace.com) (cnbc.com) The timing lands in the middle of a tougher race for obesity and diabetes drugs. Reuters reported Tuesday that Novo Nordisk has fallen behind Eli Lilly in the weight-loss market, and CNBC reported in February that Lilly had taken a clear edge in market share. (aol.com) (cnbc.com) Investors treated the deal as an execution story as much as a science story. CNBC reported Novo Nordisk shares were up 2.8% shortly after the opening bell on April 14. (cnbc.com) Novo Nordisk has already been building an artificial intelligence stack outside this deal. Nvidia said in June 2025 that it was working with Novo Nordisk and the Danish Centre for AI Innovation on custom models, agents and the Gefion sovereign artificial intelligence supercomputer for early research and clinical development. (investor.nvidia.com) Novo Nordisk said this OpenAI agreement includes strict data protection, governance and human oversight. That language addresses a central problem in drug development: companies want faster analysis, but regulated decisions on patients, factories and medicines still need documented controls and human review. (biospace.com) The company’s own pitch is speed. Mike Doustdar, Novo Nordisk’s chief executive, said the goal is to test hypotheses faster, find therapies earlier and move medicines through the pipeline with less delay. (biospace.com)